Report Overview
The global diaphragm pacing therapy system market size was valued at USD 7.6 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 4.6% from 2021 to 2028. The growing prevalence of disorders including sleep apnea, amyotrophic lateral sclerosis, and spinal cord injuries is expected to support the growth of the market. The diaphragm pacemaker is more accurate, comfortable compared to the mechanical ventilators and reduces the risk of upper airway infections such as ventilator-associated pneumonia. In addition, the favorable regulatory policies and approvals are fueling the adoption of the diaphragm pacing therapy systems. The COVID-19 pandemic propelled the demand owing to the upsurge in the ventilation requirements to provide respiratory care for the infected patients.
The diaphragm pacing therapy system reduces the dependence on mechanical ventilators and most patients prefer the diaphragm pacemaker as it facilitates normal breathing and better speech patterns, improved sense of smell, and ease of drinking and eating activities. In addition, the silent operation and functioning of a breathing pacemaker and the size of the device enabling mobility is further expected to boost the adoption of the diaphragm pacing therapy systems.
Product Insights
In 2020, the external diaphragm pacemaker segment dominated the market and accounted for the largest revenue share of 57.8%. Based on the product, the market for the diaphragm pacing therapy system is segmented into external diaphragm pacemaker and diaphragm pacemaker.
The external diaphragm pacemaker segment is gaining popularity owing to the rise in treatment of conditions such as cervical spinal cord injury and congenital central hypoventilation syndrome. The diaphragm pacemaker decreases the power outages concern and external power source requirement, and the convenience of movement and silent functioning further supports the market growth.
Application Insights
The spinal cord injury segment dominated the market and accounted for the largest revenue share of 45.5% in 2020 owing to the growing number of spinal cord injuries annually worldwide. According to the National Spinal Cord Injury Statistical Center, around 17,000 new spinal cord injury cases are reported every year in the U.S.
Moreover, the upsurge in accidents and falls, and injury during sports/recreation activities boost the prevalence of spinal cord injury and the number of patients suffering resulting in the demand for diaphragm pacing therapy systems. Furthermore, the growing prevalence of amyotrophic lateral sclerosis is expected to support the market growth of the diaphragm pacing therapy system. Amyotrophic lateral sclerosis is most common in the geriatric population, and it is reported that around 5,000 new cases are diagnosed each year in the U.S.
Regional Insights
North America dominated the diaphragm pacing therapy system market and accounted for the largest revenue share of 59.7% in 2020. The market is expected to grow well in the region over the forecast period owing to the prevalence of breathing disorders including sleep apnea, amyotrophic lateral sclerosis, and spinal cord injuries in the region. Furthermore, the improving healthcare expenditure and the growing disposable incomes of patients are expected to contribute to market growth in the region.
In Asia Pacific, the market is expected to witness the fastest growth rate over the forecast period. This is owing to the rising prevalence of breathing disorders, improving healthcare expenditure, supportive government initiatives, growing focus on R&D activities, and technological development to improve the healthcare infrastructure.
Key Companies & Market Share Insights
Technological developments in the healthcare sector have led to further innovation and development by the market players to meet the growing demand. Moreover, the ongoing COVID-19 pandemic has resulted in the surge of critical patients requiring mechanical ventilation for a prolonged period. This has burdened the healthcare systems and ICU resources with an unprecedented demand for ventilators and the patients face the risk of developing ventilator-induced diaphragm dysfunction. Lungpacer Medical’s diaphragm pacing therapy system received the U.S. FDA Emergency Use Authorization in April 2020 for COVID-19 patients.
In addition, Synapse Biomedical received the Emergency Use Authorization by the U.S. FDA for its TransAeris diaphragm pacing therapy system. The TransAeris system received CE Mark approval in 2018 and is under clinical investigation in the U.S. Some of the prominent players in the diaphragm pacing therapy system market include:
Lungpacer Medical Inc.
Avery Biomedical Devices, Inc.
Synapse Biomedical
Atrotech